Medivir AB Release: Phase II All-Oral Combination Studies of Simeprevir, TMC647055 and IDX719 for the Treatment of Hepatitis C to be Initiated Shortly

Published: Jan 28, 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy. The collaboration will evaluate combinations including simeprevir (TMC435), a once -daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once-daily NNI (non-nucleoside inhibitor) of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.

Back to news